Aytu Business Model Canvas

Partnering with national wholesalers (McKesson, Cardinal, AmerisourceBergen cover ~85% of U.S. drug distribution), specialty distributors and PBMs expands Aytu’s availability and access. PBM relationships, which manage roughly 80% of prescription lives, drive formulary placement and rebate structures. Efficient distribution improves service levels and reduces stockouts, supporting reach into retail and specialty pharmacies.

Partner with originators to in-license pediatric/primary care assets (royalties low-single to mid-teens) and use GMP CMOs (global CMO market $82B in 2024) for 10–25% lower COGS. National wholesalers (~85% U.S. reach) and PBMs (~80% lives) expand access. Alimera merger Jan 2024 creates shared services and cross-sell scale.

Run post-marketing studies, RWE and safety surveillance to boost adoption, leveraging a global RWE market that surpassed $3 billion in 2024; engage KOLs and advisory boards for real-world validation; provide compliant scientific exchange and education across HCP channels; feed insights into labeling and positioning to support uptake and reimbursement decisions.

Source and optimize primary care/pediatric assets addressing unmet needs (primary care ~50% of US outpatient visits); negotiate rights, milestones, and payer-ready dossiers. Secure coverage via rebates (20–50% in 2024), HEOR ($50–150k/QALY) and patient-access programs while managing gross-to-net. Drive adoption with RWE (> $3B market 2024), field sales to ~67,000 pediatricians, cGMP/PV (15-day expedited, PSUR 6m→annual) and labeling across 24 EU languages.

Existing NDAs, ANDAs and supplements underpin Aytu’s commercialization by providing market entry pathways and exclusivity leverage. Robust QMS and pharmacovigilance systems ensure ongoing regulatory compliance and patient safety. Comprehensive documentation and audit readiness reduce inspection-related risk and downtime. These resources facilitate rapid regulatory changes and timely submissions to regulators.

Held prescription rights, trademarks, and approved indications enable outpatient commercialization and reimbursement access. Established sales, market access, and medical teams sustain HCP networks and formulary traction. Linked claims/prescription/CRM and safety/HEOR datasets plus Alimera corporate access support forecasting, access negotiations, and scaled operations in 2024.

Provide user-friendly formulations and clear dosing to reduce administration errors; WHO estimates adherence for chronic diseases in developed countries averages 50%. Education and automated reminders help families manage therapy and refill/savings tools simplify continuity, addressing the $100–300 billion annual US cost attributed to medication nonadherence. Better adherence translates into measurable outcome gains and lower utilization.

Clinically differentiated therapies targeting pediatrics (22% of US pop) drive prescriber preference via superior efficacy, safety and RWE. Broad payer access (>80% formulary 2024), rebates and copay support cut abandonment ~30% and raise adherence vs ~50% baseline. Reliable supply (98% fill rate target) and 24h response preserve continuity and accelerate uptake.

Patient support programs deliver onboarding, copay assistance and reimbursement navigation, plus adherence tools and education; 2024 industry data show such programs can boost treatment initiation by up to 30% and improve persistence roughly 20%, while centralized patient hubs streamline prior authorizations—cutting turnaround time and abandonment rates significantly and improving net prescription fill rates.

Dedicated omnichannel HCP engagement (68% prefer integrated outreach) with samples (+~40% prescribing) and monthly touchpoints; payer/PBM relations (control ~80% US scripts) with performance contracts protect access. Patient support programs raise starts ~30% and persistence ~20%, while KOL/CME ($6.2B 2024) and pharmacy partnerships lift fill rates and reduce PA turnaround.

National wholesalers, led by the three large distributors McKesson, AmerisourceBergen and Cardinal Health, move product to pharmacies and specialty sites. This network ensures broad U.S. geographic coverage and rapid replenishment. Contract terms and SLAs govern inventory, billing and service levels. Specialty distributors also support buy-and-bill workflows where applicable.

Multichannel outreach combines ~1,062,205 US physicians (AAMC 2023) via field reps/MSLs and digital (>50% HCP interactions, IQVIA 2024) to drive uptake across a 6.44B‑script market (IQVIA 2023). Distribution via McKesson/AmerisourceBergen/Cardinal Health plus specialty distributors ensures national reach and buy‑and‑bill support. Pharmacy and payer channels (≈21,000 retail pharmacies, 2024) elevate adherence (~+15%) and forecast accuracy (~+20%).

Target payers and PBMs across commercial (~180M covered lives), Medicaid (~82M enrollees in 2024), and Medicare Part D (~51M enrollees) demand clear HEOR demonstrating cost-effectiveness and QALY gains to justify placement. Negotiate value-based contracting, rebates, and utilization edits with the three major PBMs that control ~80% of claims. Contract terms must limit patient cost share and prior authorization to optimize adherence and outcomes.

Pediatricians (~67,000) and family physicians (~92,000) drive pediatric prescriptions; PCPs (~210,000) provide baseline volume. Payers/PBMs (commercial ~180M lives, Medicaid ~82M, Medicare D ~51M) require HEOR and favorable coverage. Patients/caregivers need affordability and support to improve ~50% adherence (+20–30% with education).

Rebates, chargebacks and admin fees paid to payers and PBMs constitute a major line-item, alongside copay assistance and patient programs that drive uptake but increase deductions. In 2024 pharmaceutical gross-to-net deductions averaged roughly 30–40% of list price, materially reducing reported revenue. Aytu manages this exposure through disciplined contracting, formulary strategies and targeted patient-program budgeting.

Aytu's cost structure is driven by CMO manufacturing (global market ~$130B in 2024), freight/distribution (5–12% of COGS), serialization/regulatory add-ons, and scale-driven unit cost declines. Commercial spend favors digital (>50% of promo budgets in 2024). Gross-to-net deductions averaged 30–40%, while late-stage R&D programs often exceed $20M per study.

Direct and indirect sales to hospitals and outpatient clinics, including volume-tier contracts, drive initiation and continuity of treatment and stabilize regional demand; in 2024 there are roughly 6,000 US hospitals and over 230,000 outpatient clinics, offering broad addressable channels. Volume-tier contracts secure predictable unit orders and revenue cadence. Institutional deals often account for the majority of early commercial uptake.

Net sales to distributors/wholesalers are Aytu’s primary revenue, recognized net of returns/chargebacks and linked to inventory dynamics and sell-through. Specialty channels account for >50% of US drug spend in 2024 while 2–3% of scripts, enabling adherence programs and payer contracting. Partnerships: median upfronts ~$5M (2024), milestones $1M–$50M, royalties 5–15%; hub services cut abandonment ~30% and boost persistence ~15% (IQVIA 2024).